Production and characterization of monoclonal antibody specific for NS3 helicase of hepatitis C virus

Hybridoma

Volumn 27, Issue 3, 2008, Pages 181-186

  Yang, Jing ^c   Lei, Ying Feng ^a   Yin, Wen ^a   Wei, San Hua ^a   An, Qun Xing ^b   Lv, Xin ^a   Hu, Xing Bin ^a   Xu, Zhi Kai ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

HELICASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2B8; NS3 HELICASE; UNCLASSIFIED DRUG; NS3 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CANCER CELL CULTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; HYBRIDOMA; IMMUNE SYSTEM; METABOLISM; METHODOLOGY; PLASMID;

HEPATITIS C VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEPACIVIRUS; HUMANS; HYBRIDOMAS; IMMUNE SYSTEM; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; PLASMIDS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 50349083513     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2007.0557     Document Type: Article

References (19)

1. Moriishi K, and Matsuura Y: Mechanisms of hepatitis C virus infection. Antivir Chem Chemother 2003;14(6):285-297.
2. Sookoian SC: New therapies on the horizon for hepatitis C. Ann Hepatol 2003;2(4):164-170.
3. Sun J, Li K, Shata MT, and Chan TS: The immunologic basis for hepatitis C infection. Curr Opin Gastroenterol 2004;20(6):598-602.
4. Huang Z, Murray MG, and Secrist JA 3rd: Recent development of therapeutics for chronic HCV infection. Antiviral Res 2006;71(2-3):351-62.
5. Blight KJ, Kolykhalov AA, Reed KE, Agapov EV, and Rice CM: Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets. Antivir Ther 1998;3(Suppl 3):71-81.
6. Fang JW, Chow V, and Lau JY: Virology of hepatitis C virus. Clin Liver Dis 1997;1(3):493-514.
7. Kwong AD, Kim JL, Rao G, Lipovsek D, and Raybuck SA: Hepatitis C virus NS3/4A protease. Antiviral Res 1998;40(1-2):1-18.
8. Gwack Y, Kim DW, Han JH, and Choe J: Characterization of RNA binding activity and RNA helicase activity of the hepatitis C virus NS3 protein. Biochem Biophys Res Commun 1996;225(2):654-659.
9. Kwong AD, Kim JL, and Lin C: Structure and function of hepatitis C virus NS3 helicase. Curr Top Microbiol Immunol 2000;242:171-196.
10. Jolivet-Reynaud C, Adida A, Michel S, Deléage G, Paranhos-Baccala G, Gonin V, Battail-Poirot N, Lacoux X, and Rolland D: Characterization of mimotopes mimicking an immunodominant conformational epitope on the hepatitis C virus NS3 helicase. J Med Virol 2004;72(3):385-395.
11. Kim JL, Morgenstern KA, Griffith JP, Dwyer MD, Thomson JA, Murcko MA, Lin C, and Caron PR: Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 1998;6(1):89-100.
12. Borowski P, Lang M, Niebuhr A, Haag A, Schmitz H, Schulze zur Wiesch J, Choe J, Siwecka MA, and Kulikowski T: Inhibition of the helicase activity of HCV NTPase/ helicase by 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide- 5′-triphosphate (ribavirin-TP). Acta Biochim Pol 2001;48(3):739-744.
13. Bretner M, Schalinski S, Borowski P, and Kulikowski T: 5′-O-fluorosulfonylbenzoyl esters of purine nucleosides as potential inhibitors of NTPase/helicase and polymerase of Flaviviridae viruses. Nucleosides Nucleotides Nucleic Acids 2003;22(5-8):1531-1533.
14. Artsaenko O, Tessmann K, Sack M, Häussinger D, and Heintges T: Abrogation of hepatitis C virus NS3 helicase enzymatic activity by recombinant human antibodies. J Gen Virol 2003;84:2323-2332.
15. Hong Z, Standring DN, Baroudy B, and Lau JY: Development of novel anti-HCV therapies: HCV protease, helicase, and polymerase as therapeutic targets. Acta Gastroenterol Belg 2000;63(2):210-212.
16. Sällberg M, Zhang ZX, Chen M, Jin L, Birkett A, Peterson DL, and Milich DR: Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus non-structural 3 protein. J Gen Virol 1996;77:2721-2728.
17. Rosen HR: Hepatitis C virus in the human liver transplantation model. Clin Liver Dis 2003;7(1):107-125.
18. Griffin H, Elston R, Jackson D, Ansell K, Coleman M, Winter G, and Doorbar J: Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J Mol Biol 2006;355(3):360-378.
19. Li L, Gondi CS, Dinh DH, Olivero WC, Gujrati M, and Rao JS: Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-kappaB transcriptional activity. Clin Cancer Res 2007;13(7):2178-2190.